DOR Biopharma’s orBec For GI Disease Misses Primary Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is relying on “volume of evidence” showing clinical benefit to win FDA approval.
You may also be interested in...
FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease
DOR BioPharma, meanwhile, has launched a Phase II trial of the oral beclomethasone dipropionate product in the prophylactic GVHD setting.
FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease
DOR BioPharma, meanwhile, has launched a Phase II trial of the oral beclomethasone dipropionate product in the prophylactic GVHD setting.
CTI Plans To File Pixantrone For Non-Hodgkin’s Lymphoma In Early 2008
First pixantrone NHL filing likely will be in the “aggressive/salvage setting,” CEO tells “The Pink Sheet” DAILY.